Indication for HDMTX  
Non-Hodgkin lymphoma 41%
Osteosarcoma 30%
Acute lymphoblastic leukemia 23%
Other malignancy 7%
Median pretreatment MTX concentration 17μM
Median time of glucarpidase dose following MTX administration 3 days
Total glucarpidase doses  
1 dose 76%
2 doses 22%
3 doses 2%
Median reduction in baseline serum MTX after first glucarpidase dose by HPLC (n = 156)  
At 15 minutes 99%
At 40 hours 99%
Adverse events  
Paresthesia 2.0%
Flushing 1.8%
Headache 1.0%
HDMTX = high-dose methotrexate; HPLC = high-performance liquid chromatography; MTX= methotrexate [36]
Table 3: Compassionate use of Glucarpidase in 492 Patients with MTX Toxicity.